ECCMID 2024

ECCMID 2024
April 27-30, 2024
Barcelona, Spain

European Society of Clinical Microbiology and Infectious Diseases.

Explore more information for Gilead COVID-19 therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (7)

    Pharmacokinetics, safety and tolerability of a single dose of Obeldesivir in healthy Japanese and white participants

    • Author(s): Peng, C
    • gs-5245
    • COVID-19
    • Poster

    Obeldesivir is efficacious as oral postexposure prophylaxis for Sudan ebolavirus infection in nonhuman primates

    • Author(s): Chu, C
    • gs-5245
    • COVID-19
    • Oral

    Impact of multiple-dose remdesivir, an intravenous COVID-19 antiviral, on CYP3A4 activity in healthy volunteers: a clinical drug-drug interaction (DDI) study with midazolam

    • Author(s): Chang, J
    • veklury
    • COVID-19
    • Poster

    Remdesivir reduces mortality in elderly patients 65+ years hospitalised for COVID-19 during Omicron

    • Author(s): Mozaffari, E
    • veklury
    • COVID-19
    • Oral

    Clinical Evaluation of Drug-Drug Interactions With Obeldesivir, a Promising Oral Antiviral Treatment

    • Author(s): Peng, C
    • gs-5245
    • COVID-19
    • Poster

    Remdesivir reduces mortality in immunocompromised patients hospitalised for COVID-19 across the pandemic and endemic eras

    • Author(s): Mozaffari, E
    • veklury
    • COVID-19
    • Poster

    Comparative effectiveness of remdesivir and dexamethasone combination therapy vs dexamethasone monotherapy in patients hospitalised for COVID-19

    • Author(s): Mozaffari, E
    • veklury
    • COVID-19
    • Poster